- Investing.com
Metrics to compare | MBIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMBIOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.4x | −3.3x | −0.3x | |
PEG Ratio | −0.02 | 0.01 | 0.00 | |
Price/Book | 0.6x | 2.7x | 2.6x | |
Price / LTM Sales | - | 6.1x | 3.1x | |
Upside (Analyst Target) | - | 149.7% | 47.6% | |
Fair Value Upside | Unlock | 11.0% | 5.6% | Unlock |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.